Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sc610 in Advanced Urinary System Tumors
NCT05633589Phase 2Unknown
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2022
- Primary completion
- May 2024
- Modality
- Stem Cell Therapies
01
Overview
Phase 2, open-label, single-arm trial of Sc610 cell in renal cell carcinoma (RCC), urothelial carcinoma (UC) and prostate adenocarcinoma, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Objective Response Rate at 12 weeks. Status: unknown.
02
Drugs
Sc610 cell
03
Conditions
renal cell carcinoma (RCC)urothelial carcinoma (UC)prostate adenocarcinoma
Beyond the preview
Go deeper on NCT05633589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05633589.